We are developing novel antibodies for the treatment of diabetic retinopathy and diabetic macular edema.
To this end, we partnered with AbCellera Biologics (NASDAQ: ABCL), a global leader in antibody drug development. This partnership will accelerate our efforts of bringing novel treatments for diabetes-related blindness to the clinic.